Lantern Pharma, Inc. (LTRN)
0.6354
-0.01
(-0.83%)
USD |
NASDAQ |
Oct 23, 16:00
0.622
-0.01
(-2.11%)
After-Hours: 20:00
Lantern Pharma Enterprise Value : 0.7855M for Oct. 23, 2026
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| October 23, 2026 | 0.7855M |
| October 22, 2026 | 0.8532M |
| October 21, 2026 | 1.412M |
| October 20, 2026 | 1.054M |
| October 19, 2026 | 0.8608M |
| October 16, 2026 | 1.207M |
| October 15, 2026 | 1.186M |
| October 14, 2026 | 1.265M |
| October 13, 2026 | 1.746M |
| October 12, 2026 | 2.082M |
| October 09, 2026 | 3.048M |
| October 08, 2026 | 3.268M |
| October 07, 2026 | 4.289M |
| October 06, 2026 | 4.847M |
| October 05, 2026 | 4.673M |
| October 02, 2026 | 3.652M |
| October 01, 2026 | 5.438M |
| September 30, 2026 | 5.565M |
| September 29, 2026 | 6.522M |
| September 28, 2026 | 6.586M |
| September 25, 2026 | 8.244M |
| September 24, 2026 | 8.117M |
| September 23, 2026 | 10.41M |
| September 22, 2026 | 10.03M |
| September 21, 2026 | 11.82M |
| Date | Value |
|---|---|
| September 18, 2026 | 12.46M |
| September 17, 2026 | 14.50M |
| September 16, 2026 | 17.30M |
| September 15, 2026 | 14.37M |
| September 14, 2026 | 14.50M |
| September 11, 2026 | 14.50M |
| September 10, 2026 | 15.13M |
| September 09, 2026 | 15.26M |
| September 08, 2026 | 16.16M |
| September 04, 2026 | 16.98M |
| September 03, 2026 | 16.54M |
| September 02, 2026 | 17.30M |
| September 01, 2026 | 18.45M |
| August 31, 2026 | 18.58M |
| August 28, 2026 | 19.09M |
| August 27, 2026 | 20.24M |
| August 26, 2026 | 20.49M |
| August 25, 2026 | 20.49M |
| August 24, 2026 | 19.60M |
| August 21, 2026 | 22.53M |
| August 20, 2026 | 21.90M |
| August 19, 2026 | 24.45M |
| August 18, 2026 | 24.83M |
| August 17, 2026 | 25.85M |
| August 14, 2026 | 26.49M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| Arrowhead Pharmaceuticals, Inc. | 7.963B |
| Oncolytics Biotech, Inc. | 58.94M |
| Sangamo Therapeutics, Inc. | 39.39M |
| Sarepta Therapeutics, Inc. | 2.130B |
| Anixa Biosciences, Inc. | 88.45M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -7.072M |
| Total Expenses (Quarterly) | 7.072M |
| EPS Diluted (Quarterly) | -0.5693 |
| Earnings Yield | -253.8% |
| Normalized Earnings Yield | -234.95 |